LUPUS NEPHRITIS (LN)

This early-stage trial is testing a type of cell therapy called CAR T-cells in people with severe, treatment-resistant lupus. The study aims to find a safe dose and see if the therapy can help control the disease. It will enroll 18 participants aged 3 to 65 who have not responded…

This is an early-stage safety study testing a single infusion of YTS109 cells in 18 adults with severe autoimmune diseases that have not responded to standard treatments. The main goal is to check for side effects and see how the body handles the cells. Researchers will also look…

This is a first-in-human study to test the safety and find the right dose of a new drug, HB2198, for people with moderate to severe lupus. About 30 participants with active lupus, including kidney involvement, will receive two doses of the drug and be followed for a year. The mai…

This is an early-stage study to check the safety of a new cell therapy called YTS109 for adults with severe autoimmune diseases that have not responded to standard treatments. About 18 participants with conditions like lupus, scleroderma, or vasculitis will receive a single infus…

This study is testing a new drug, HLX79, given alongside an existing drug called rituximab, to see if it is safe and can help control active kidney disease caused by membranous nephropathy or lupus. It will involve about 24 adults who have not responded well to standard care. The…

This study is testing whether a new daily pill called HSK39297 can help control lupus nephritis, a serious kidney disease caused by lupus. About 105 adults with active kidney inflammation will take either the real pill or a placebo, along with standard care, to see if it reduces …

This early-stage study is testing two new antibody drugs for people with lupus nephritis, a serious kidney complication of lupus. The main goal is to check how safe and tolerable these experimental treatments are when given for a short period. The study will enroll 90 participant…

This early-stage study is testing a new oral drug called ONTO1 for people with lupus, including a serious kidney complication called lupus nephritis. The main goal is to find the highest safe dose and see if it helps improve symptoms when taken alongside standard lupus medication…

This study is testing a personalized cell therapy called CART19 for adolescents and young adults with severe lupus that hasn't responded to standard treatments. Doctors will collect a patient's own immune cells, modify them to target lupus-causing B cells, and reinfuse them. The …

This is an early-stage study to check the safety of a new cell therapy called YTS109 in adults with severe autoimmune diseases that have not improved with standard treatments. About 18 participants with conditions like lupus, Sjogren's syndrome, or vasculitis will receive a singl…

This study compares two newer biologic drugs (belimumab and telitacicept) against the current standard treatment for lupus nephritis, a serious kidney complication of lupus. Fifty patients with active kidney inflammation will receive either a biologic drug alone, standard therapy…

This is a large online registry, not a treatment study. Its purpose is to collect information directly from up to 10,000 people living with lupus to better understand their diagnosis journey, treatments, and how the disease affects their daily life and work. Participants complete…